Showing results (201-210 of 281) with videos related to
Sort By:
Pageof 29
Circulation. Cardiovascular Interventions|April 11, 2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, et al.Journal of the American Heart Association|March 18, 2026
Clinical, Functional, and Quality-of-Life Outcomes After Contemporary Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation in the Very ElderlyMatthew J Price, Gagan D Singh, Jason H Rogers, et al.JACC. Cardiovascular Interventions|February 24, 2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])Harvey D White, Deepak L Bhatt, C Michael Gibson, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 26, 2011
Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheterDavid E Kandzari, Ahmad A Zankar, Paul S Teirstein, et al.International Journal of Cardiology|December 20, 2018
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trialJeremie Abtan, Gregory Ducrocq, Ph Gabriel Steg, et al.American Heart Journal|May 22, 2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trialSergio Leonardi, Kenneth W Mahaffey, Harvey D White, et al.American Heart Journal|February 4, 2026
Left atrial appendage occlusion versus NOACs in patients with atrial fibrillation: Rationale and design of the CATALYST TrialVivek Y Reddy, Elaine Hylek, A John Camm, et al.Journal of Cardiovascular Pharmacology and Therapeutics|December 31, 2005
Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarctionRaj R Makkar, Matthew J Price, Michael Lill, et al.Circulation. Cardiovascular Interventions|February 24, 2022
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPIONBenjamin E Peterson, Robert A Harrington, Gregg W Stone, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 8, 2014
Conversations in cardiology: bridging antiplatelet therapy before surgeryMorton J Kern, Robert J Applegate, Malcolm Bell, et al.Pageof 29